References
- Price D. The use of omalizumab in asthma. Prim Care Respir J 2008; 17:62–72.
- Asai N, Ohkuni Y, Komatsu A, Matsunuma R, Nakashima K, Kaneko N. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE. J Bras Pneumol 2011; 37:567–570.
- Evans TM, Rundell KW, Beck KC, Levine AM, Baumann JM. Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. Chest 2005; 128:2412–2419.
- Ohishi J, Kurosawa H, Shimizu Y, Tasaku, Y, Kobayashi, D, Masuda, M, Hida W, Kohzuki M. Three dimensional color images of oscillatory properties of respiratory system. Am J Respir Crit Care Med 2009; 179:A6074.
- Mori K, Shirai T, Mikamo M, Akita T, Morita S, Asada K, Fujii M, Suda T, Chida K. Colored 3-dimensional analyses of respiratory resistance and reactance in COPD and asthma. COPD 2011; 8:456–463.
- van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011; 139:190–193.
- Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011; 7:9.
- Humbert M, Menz G, Ying S, Robinson DS, Durham SR, Kay AB. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528–533.
- Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J 2000; 16:609–614.
- Ying S, Humbert M, Meng Q, Pfister R, Menz G, Gould HJ, Kay AB, Durham SR. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol 2001; 107:686–692.
- Holgate ST, Djukanović R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35:408–416.
- Naqvi M, Choudhry S, Tsai HJ, Thyne S, Navarro D, Nazario S, Rodriguez-Santana JR, Casal J, Torres A, Chapela R, Watson HG, Meade K, Rodriguez-Cintron W, Lenoir M, Avila PC, Burchard EG. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. J Allergy Clin Immunol 2007; 120:137–143.
- Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009; 103:1098–1113.
- Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378–1386.
- Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009; 64:1780–1787.
- Ankerst J, Nopp A, Johansson SG, Adédoyin J, Oman H. Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 2010; 152:71–74.
- Olson R, Karpink MH, Shelanski S, Atkins PC, Zweiman B. Skin reactivity to codeine and histamine during prolonged corticosteroid therapy. J Allergy Clin Immunol 1990; 86:153–159.
- Slott RI, Zweiman B. A controlled study of the effect of corticosteroids on immediate skin test reactivity. J Allergy Clin Immunol 1974; 54: 229–234.